Aubagio (Teriflunomide) Patent Expiration, LOE Window & CMS Spending

Aubagio (Teriflunomide) by Sanofi: FDA Orange Book LOE 2034-08-04, 13 AB generics, $170.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN202992 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-08-04
Orange Book Patents (*PED Extensions)6 patents (3 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$170.7M
2024 Medicare Part D Spend$148.5M
2024 Medicaid Spend$22.2M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 21.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.